Histone Lactylation-mediated PKM2 promotes gemcitabine resistance in pancreatic adenocarcinoma via the AKT/mTOR/SREBP1 Axis

QingHua Yin, Yang Zhou, Kai Liu, Xu Zhang

Open source

DOI
10.1016/j.bbagen.2026.130995
Published
2026-09
Container
Biochimica et Biophysica Acta (BBA) - General Subjects
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bbagen.2026.130995,
  title = {Histone Lactylation-mediated PKM2 promotes gemcitabine resistance in pancreatic adenocarcinoma via the AKT/mTOR/SREBP1 Axis},
  author = {QingHua Yin and Yang Zhou and Kai Liu and Xu Zhang},
  year = {2026},
  journal = {Biochimica et Biophysica Acta (BBA) - General Subjects},
  doi = {10.1016/j.bbagen.2026.130995},
  url = {https://doi.org/10.1016/j.bbagen.2026.130995}
}

RIS

TY  - JOUR
TI  - Histone Lactylation-mediated PKM2 promotes gemcitabine resistance in pancreatic adenocarcinoma via the AKT/mTOR/SREBP1 Axis
AU  - QingHua Yin
AU  - Yang Zhou
AU  - Kai Liu
AU  - Xu Zhang
PY  - 2026
JO  - Biochimica et Biophysica Acta (BBA) - General Subjects
DO  - 10.1016/j.bbagen.2026.130995
UR  - https://doi.org/10.1016/j.bbagen.2026.130995
ER  - 

APA

Yin, Q., Zhou, Y., Liu, K., & Zhang, X. (2026). Histone Lactylation-mediated PKM2 promotes gemcitabine resistance in pancreatic adenocarcinoma via the AKT/mTOR/SREBP1 Axis. Biochimica et Biophysica Acta (BBA) - General Subjects. https://doi.org/10.1016/j.bbagen.2026.130995

Source records